slide1
Download
Skip this Video
Download Presentation
Vaccines

Loading in 2 Seconds...

play fullscreen
1 / 37

Vaccines - PowerPoint PPT Presentation


  • 79 Views
  • Uploaded on

Vaccines. Dr T. Espanol Immunology Unit University Hospital Vall d´ Hebron Barcelona. Effective vaccines: rapid decrease in infections in the general population.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Vaccines' - maxwell-harvey


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
Vaccines

Dr T. Espanol

Immunology Unit

University Hospital Vall d´ Hebron

Barcelona

slide5
If protective immune response levels are high in the general population, the possibility of dissemination of an infection is low.

For this reason it is so important to follow the immunisation programmes

until the infection can be considered erradicated

Measles cases / protection

slide6
Red cells

Specific response

Platelets

Specific response

Innate response / inflammation

slide7
How and where the infections enter the body

Distribution and recirculation

slide8
A main characteristic of the immune response is its ability to

recognise antigens in any part of the body and distribute effector

cells and antibodies throughout the organism

slide9
Most cells of the immune response recirculate throughout the

body and in lymph nodes they mature to produce antibodies or cytotoxic cells that leave the lymph nodes for any part of the body

slide13
Innate response

Specific T-cell response

slide14
Specific T-cell response begins with recognition of the “intruder”

by monocyte/macrophages (through some receptors), and the presentation of antigens (part of the proteins) to the super-specific

T-cell receptor

slide15
1st

2nd

Innate response/inflammation is essential to elicit a specific response

slide16
The antigen is presented to the T cells to begin complex cell activation,

induce several effector mechanisms, collaborate with B cells to produce antibodies and secrete cytokines that mature cytotoxic cells, etc

slide17
HLA antigens are inherited characteristics of all human cells

(except red cells and the cornea) and their function is to recognise the “identity” of our cells versus foreign cells or cells with foreign antigens

Correlation between some HLA characteristics and diseases

slide18
The job of cytotoxic cells is to kill the cells recognised as “foreign” (transplants) or which have foreign “particles” in the membrane (virus-infected cells)
slide20
Immunoglobulins are proteins with several functions

The Fab segment is able to recognise many different antigens

slide21
Total diversity: Ig´s

T-cell receptors:

slide22
Main characteristics of the immune response:
  • - immunological memory (used in vaccination)
  • high specificity (used in vaccination)
  • recirculation (oral vaccines)
  • a very high energy-consuming system
slide23
If there is a chronic inflammatory response and no antibodies to eliminate the bacteria, lesions appear in different organs
slide25
Extracellular bacteria: pneumococcus

haemophilus

streptococcus, etc

Intracellular bacteria: tuberculosis

salmonella, etc

Viral infections : polio

measles

HIV, etc

slide26
Vaccines to produce antibodies to bacterial infections and toxinse.g. Pneumococcus, tetanus toxins  must stimulate the maturation of B cells (a T-cell collaboration is needed!)

Vaccines to prevent viral infections e.g. measles, polio, HIV must stimulate cytotoxic cells (T cells)

Most of them are very effective in healthy persons.

- HIV vaccine not achieved to date due to the extreme

variability of the virus and because it is a retrovirus

- Anti-’flu vaccines. Effective but the antigen must be

changed periodically due to changes in the virus

Vaccines against parasites (e.g. Malaria) very difficult to achieve Not much research has been done ( affects poor countries !!!)

slide27
Types of vaccines :

Attenuated (“live “ vaccines) BCG, measles, chicken pox...

Inactivated most anti-bacterials, polio i.m., ‘flu...

Toxoids  tetanus

Conjugated (polysaccharides and proteins)  Haemophilus

Recombinant Hepatitis B

DNA vaccines  under development

New vaccines :

Human Papilloma virus recombinant

Rotavirus  attenuated

slide29
Therapeutic vaccines : to stimulate the immune response to a

specific microorganism that is infecting a patient with poor response

- Anti-tumour “vaccines”: Use of presenting cells with incorporated tumoral antigens  to induce a stronger specific response

- Immunotherapy in allergic diseases: to inhibit specific IgE synthesis with small and repeated amounts of the allergen (tolerance)

slide33
GENERAL RULES :
  • - if an antibody response or a T-cell response cannot be produced,
  • vaccines will not be useful
  • live or attenuated vaccines can produce the same disease in an
  • immunodeficient or immunocompromised individual (e.g. oral
  • polio)

Vaccines against bacteria are of no use in antibody deficiency

syndromes. In these cases, theoretically, vaccines against virus COULD (?) be given , but there is no way to know whether they are effective.

In any event, inactivated or recombinant vaccines should

ALWAYS be used !!!

slide36
And it is important for PID patients that national levels of protection against the majority of microorganisms are optimum.
slide37
Some references

- François G et al. Vaccine safety controversies and the future vaccination programs. Ped Infect Dis J 2005; 24(11) 953-61

- Ada, G. Vaccines and vaccination. N. Engl.J. Med 2001; 345: 1042-1053.

- Ljungman, P., Engelhard, D., de la Camara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases working party of the EBMT. Bone Marrow Transplant 2005; 35: 737-46.

- Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112: 66-73

- Witney, CG, Farley, MM, Hadler, J. et al Decline in Invasive Penumococcal Disease after the Introduction of Protein-Polysaccharide Conjugate Vaccine. N.Engl.J.Med 2003; 348: 1737-46

ad